Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4.28B 641M 573M 530M 480M 899M 61B 914M 6.38B 2.52B 31.9B 2.41B 2.35B 101B P/E 2024
217x
P/E 2025 322x
Enterprise Value 5.14B 770M 689M 637M 577M 1.08B 73.27B 1.1B 7.67B 3.03B 38.32B 2.89B 2.83B 121B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.3%
Yield 2024
0.37%
Yield 2025 0.06%
07:50pm Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
09-21 Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) added to S&P Global BMI Index CI
08-20 Realcan Pharmaceutical Group Co., Ltd. Approves the Election of Lv Kaiqiang and Wu Bin as Independent Director CI
08-20 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-07 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
30/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day+0.34%
1 week-3.96%
Current month-11.01%
1 month-12.35%
3 months+11.49%
6 months-9.63%
Current year-9.63%
1 week 2.72
Extreme 2.72
3.05
1 month 2.72
Extreme 2.72
3.38
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 26/04/2021
President 61 26/05/2023
Corporate Officer/Principal 40 30/10/2019
Director TitleAgeSince
Chairman 61 21/11/2009
Director/Board Member 43 21/11/2009
Chairman 48 08/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/23 A Sell

Founder

15,000,000 1.2902%
3/30/23 A Sell

Founder

13,040,000 1.1260%
3/30/23 A Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-3.96%+0.34%-13.13% 639M
+0.45%+1.76%+54.96%+118.11% 1,135B
+0.94%+4.20%+39.86%+75.69% 635B
+0.39%+0.46%+25.77%+97.40% 505B
+1.43%+4.56%+46.20%+66.91% 378B
-3.21%-3.66%+60.72%+35.68% 358B
-0.41%+2.23%+22.48%+48.54% 295B
+0.23%+3.28%+2.57%+21.89% 266B
+1.22%+2.81%+52.40%+63.37% 237B
+1.70%+1.60%+31.21%+102.44% 193B
Average +0.28%+1.15%+33.65%+61.69% 400.43B
Weighted average by Cap. +0.29%+1.55%+41.39%+81.02%

Financials

2024 2025
Net sales 7.97B 1.19B 1.07B 988M 894M 1.67B 114B 1.7B 11.89B 4.7B 59.41B 4.48B 4.39B 188B 7.3B 1.09B 978M 905M 819M 1.53B 104B 1.56B 10.89B 4.31B 54.41B 4.1B 4.02B 172B
Net income 20.62M 3.09M 2.76M 2.56M 2.32M 4.33M 294M 4.4M 30.77M 12.17M 154M 11.6M 11.35M 487M 16.07M 2.41M 2.15M 1.99M 1.8M 3.38M 229M 3.43M 23.98M 9.48M 120M 9.04M 8.85M 380M
Net Debt 1.6B 239M 214M 198M 179M 335M 22.75B 341M 2.38B 942M 11.9B 897M 878M 37.67B 860M 129M 115M 107M 96.58M 181M 12.27B 184M 1.28B 508M 6.42B 484M 474M 20.32B
Projected Income Statement - Annual - Realcan Pharmaceutical Group Co., Ltd.
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
26/10/26 CN¥2.910 +0.34% 44,423,600
23/10/26 CN¥2.900 +1.75% 61,091,800
22/10/26 CN¥2.850 -4.36% 64,525,600
21/10/26 CN¥2.980 +0.68% 56,570,141
20/10/26 CN¥2.960 -0.67% 46,694,300
  1. Stock Market
  2. Stocks
  3. 002589 Stock